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a b s t r a c t
Dengue virus (DENV) is transmitted in the saliva of the mosquito vector Aedes aegypti during blood meal
acquisition. This saliva is composed of numerous proteins with the capacity to disrupt hemostasis or
modulate the vertebrate immune response. One such protein, termed “aegyptin,” is an allergen and
inhibitor of clot formation, and has been found in decreased abundance in the saliva of DENV-infected
mosquitoes. To examine the inﬂuence of aegyptin on DENV infection of the vertebrate, we inoculated
IRF-3/7/ / mice with DENV serotype 2 strain 1232 with and without co-inoculation of aegyptin.
Mice that received aegyptin exhibited decreased DENV titers in inoculation sites and in circulation, as
well as increased concentrations of GM-CSF, IFN-γ, IL-5, and IL-6, at 48 h post-inoculation when
compared to mice that received inoculation of DENV alone. These and other data suggest that aegyptin
impacts DENV perpetuation via elevated induction of the immune response.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Dengue virus (DENV) is maintained in a primarily anthropo-
notic cycle between humans and the Aedes aegypti mosquito
(WHO, 2010). Feeding by A. aegypti on vertebrate hosts results in
the simultaneous introduction of virus and saliva into the skin
(Grifﬁths and Gordon, 1952; Styer et al., 2007; Turell and
Spielman, 1992; Turell et al., 1995). This saliva contains many
pharmacologically important proteins that modulate host hemos-
tasis and immune responses, which in turn facilitate blood feeding
and virus transmission (Schneider and Higgs, 2008; Ribeiro et al.,
2007; Calvo et al., 2007). Additionally, A. aegypti saliva has been
shown to contain allergenic proteins (Peng and Simons, 2007). The
vertebrate immune response to DENV infection may be altered as
a result of the immunogenic nature of these salivary proteins,
thereby altering DENV infection kinetics.
The effects of salivary proteins on mosquito-borne viral infec-
tion have been reviewed previously, and include alterations in
cytokine production and potentiation of infection in otherwise
non-permissive models (Schneider and Higgs, 2008; Schneider
et al., 2004; Osorio et al., 1996). More recently, A. aegypti saliva has
been shown to induce alterations in leukocyte recruitment during
West Nile virus infection, and shift the cytokine proﬁle from a Th1
toward a Th2 type immune response during chikungunya virus
infection (Schneider et al., 2010; Thangamani et al., 2010). In the
context of DENV infection, the addition of A. aegypti saliva in vitro
resulted in the reduced production of antimicrobial peptides and
interferons, thereby increasing viral titers (Surasombatpattana
et al., 2012). Allowing A. aegypti to feed on IRF-3/7 /  / mice
immediately before intradermal injection of DENV resulted in the
down-regulation of multiple innate immune transcripts and
increased DENV viremia titers (McCracken et al., 2014). Addition-
ally, A. aegypti saliva has increased the prevalence of disease signs
and extended the viremic period in DENV-infected, humanized
mice (Cox et al., 2012).
As an important step in the characterization of mosquito saliva,
researchers have examined the composition of A. aegypti salivary
glands at the transcriptional level and protein expression level
(Ribeiro et al., 2007; Champagne et al., 1995; Valenzuela et al.,
2002; Smartt et al., 1995; Thangamani and Wikel 2009; Almeras
et al., 2010, 2009; Wasinpiyamongkol et al., 2010). Work has been
done to ascribe function to some of these salivary components and
investigate their individual effects on vertebrate hemostasis and
immune response outside the context of a viral infection (Calvo
et al., 2007; Champagne et al., 1995; Ribeiro and Francischetti
2003; Ribeiro 1995; Boppana et al., 2009; Calvo et al., 2006, 2010;
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Champagne and Ribeiro, 1994; Stark and James, 1998; Zeidner
et al., 1999). Additionally, A. aegypti saliva has been shown to elicit
speciﬁc IgG and IgE responses in humans (Wasinpiyamongkol
et al., 2010; Remoue et al., 2007). Recent studies have described
the effect that DENV infection has on protein expression in the
salivary glands or expectorated saliva and postulates how these
changes could be relevant to virus transmission (Chisenhall et al.,
2014a, 2014b). Among the proteins that were found in lower
abundance in A. aegypti saliva as a result of DENV infection was a
member of the GE-rich 30 kDa antigen family, designated in
A. aegypti as “aegyptins” (Calvo et al., 2007; Ribeiro et al., 2010).
The decreased expression of this protein during DENV infection
could suggest that it supplies negative pressure on viral perpetua-
tion. This pressure may be inherent to the aegyptin protein family
and perhaps impacts transmission or establishment of infection.
The archetypal protein of the 30 kDa antigen family in
A. aegypti has been shown to perform two distinct roles within
the vertebrate. First, as an allergen, aegyptin has been shown to
induce positive skin-test reactions and antibody responses in
sensitized humans (Peng and Simons, 2004). Second, aegyptin
has demonstrated the ability to bind to collagen, inhibiting platelet
aggregation and interaction with von Willebrand factor, which
could facilitate blood feeding by reducing the formation of blood
clots (Calvo et al., 2007, 2010).
Due to the involvement of aegyptin with both the vertebrate
immune response and the clotting cascade, we explored the
impact of aegyptin within the context of a DENV infection.
Recombinant aegyptin was used for in vivo evaluation of the
effects of this protein on the murine immune response to DENV
and the resulting infection in the inoculation site, draining lymph




DENV titers were measured at 48 h post-inoculation in the
inoculated ears and draining submandibular lymph nodes of mice
inoculated with DENVþaegyptin or DENV only. DENV titers in the
ears of DENVþaegyptin inoculated mice had a mean of 1.65
106 PFU*/mL, while the inoculated ears of mice that received DENV
alone had a signiﬁcantly greater mean titer of 3.38106 PFU*/mL
(p¼0.0057). The lymph nodes of DENVþaegyptin inoculated mice
did not differ signiﬁcantly from mice inoculated with DENV alone
(p¼0.0678) with mean titers of 7.21105 and 1.42106 PFU*/mL,
respectively. (Fig. 1)
Cytokine responses
The cytokines GM-CSF, IFN-γ, IP-10, TNF-α, IL-1a, IL-2, IL-4, IL-5,
IL-6, IL-10, and IL-12p70 were assessed in the inoculated ears,
draining submandibular lymph nodes, and the serum of mice
inoculated with DENVþaegyptin, DENV alone, aegyptin alone, and
those that received a mock inoculation as outlined above. All
differences stated are signiﬁcant (pr0.05). In the ears (Fig. 2A),
the concentrations of IFN-γ and IL-2 were found to differ between
all treatment groups except DENVþaegyptin compared to DENV
alone. IL-10 differed among all comparisons except DENVþ
aegyptin compared to DENV alone and aegyptin alone compared
to mock. IP-10 differed when comparing DENVþaegyptin to
aegyptin alone or mock, and mock differed from DENV alone.
IL-6 differed only in ears inoculated with aegyptin alone compared
to DENV alone. IL-4 and IL-12p70 were below the limit of detection
in all treatment groups. All other cytokines displayed no signiﬁcant
differences between treatment groups, and no cytokines were
found to differ in the ear between DENVþaegyptin and DENV
alone (p40.05). In the draining submandibular lymph nodes
(Fig. 2B), GM-CSF, IFN-γ, and IL-6 were found to differ signiﬁcantly
between DENVþaegyptin compared to DENV alone, aegyptin alone,
and mock treatment mice. IL-5 in DENVþaegyptin inoculated mice
differed from mice inoculated with DENV alone. TNF-α differed
among all comparisons except DENVþaegyptin compared to DENV
alone and aegyptin alone compared to mock inoculated mice. IP-10
differed only between aegyptin alone compared to DENVþaegyptin
or DENV alone. Again, IL-4 and IL-12p70 were below the limit of
detection and all other cytokines displayed no signiﬁcance between
treatment groups (p40.05). Cytokine concentrations in the serum
were not found to be signiﬁcantly different between any treatment
groups (p40.05, data not shown).
Hematology
The percentages (counts) and concentration (per μL) of circu-
lating leukocytes were determined as described above for all four
treatment groups. All stated differences are signiﬁcant (pr0.05)
as determined using odds ratios. The eosinophil counts in the
DENVþaegyptin inoculated mice were more likely to be elevated
when compared to mice inoculated with DENV alone, as well as in
mock inoculation compared to DENV alone. The monocyte counts
were correspondingly more likely to be lower in these compar-
isons as well as in mice inoculated with aegyptin alone compared
to DENV alone. Neutrophil counts were found more likely to be
lower between mice inoculated with aegyptin alone as compared
to all other treatments. Lymphocyte counts were correspondingly
more likely to be higher in the aegyptin alone group compared to
all other treatment groups, as well as in mock inoculated mice
compared to those inoculated with DENV alone. All other compar-
isons of counts, the leukocyte concentrations (data not shown),
and total nucleated cell concentrations (data not shown) were not
found to differ signiﬁcantly (p40.05). The comparison of leuko-
cyte counts from the aegyptinþvirus inoculation cohort as com-
pared to the virus only inoculation cohort is displayed in Fig. 3. The
odds ratios with associated 95% conﬁdence intervals and p values
for this and all other comparisons of counts are in Supplement 1.
Fig. 1. DENV titers in inoculated ears and draining submandibular lymph nodes at
48 h post-inoculation. DENV titers, expressed as PFU-equivalents/mL (PFU*/mL) were
signiﬁcantly lower in the ears of mice that received co-inoculation of DENVþaegyptin
(AV) as compared to the cohort that received DENV only (V, p¼0.0057), as indicated
by an asterisk. DENV titers were not found to be signiﬁcantly different in the lymph
nodes (p¼0.0678), although they followed a similar trend as those of the ears.
Associated bars represent standard error of the means.
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Fig. 2. Cytokine concentrations in the inoculated ears (A) and draining submandibular lymph nodes (B) at 48 h post-inoculation. The y-axis displays concentration in pg/mL
and the x-axis denotes treatment groups (AV¼DENVþaegyptin, V¼DENV only, A¼aegyptin only,M¼mock inoculation). Signiﬁcant comparisons are indicated by an asterisk
(pr0.05). Associated bars represent standard error of the means.
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Serially bled mice
Viremia
DENV viremia titers were measured each day for six days
following inoculation in both the DENVþaegyptin and DENV
alone treatment groups. These titers were found to differ signiﬁ-
cantly between the two treatment groups on day two post-
inoculation, which corresponds to the difference observed in the
inoculation sites at 48 h post-inoculation, and on day ﬁve post-
inoculation (pr0.05) (Fig. 4).
Discussion
The 30 kDa antigen family of proteins contains multiple alleles
and splice variants that are compositionally similar, consisting of
two domains and possessing similar molecular weights. Prior
analysis has revealed that these aegyptins represent two subclades
within Aedes (designated I and II) (Ribeiro et al., 2010). Analysis of
expectorated saliva from DENV2 infected A. aegypti using 2D gel
electrophoresis and LC-MS/MS has previously identiﬁed a sub-
clade I aegyptin (gi|18568322) that was reduced 14.1-fold when
compared to saliva from uninfected mosquitoes (Chisenhall et al.,
2014b). This aegyptin has also been referred to as “SAAG-4,” which
has demonstrated the capacity to suppress IFN-γ expression while
elevating IL-4 expression by CD4þT cells outside the context of a
viral infection (Boppana et al., 2009). The recombinant aegyptin
used in the current study in vivo is a member of subclade II (gi|
94468546) and is the archetypal aegyptin utilized in the biophar-
maceutical characterization of the capacity to inhibit clotting
(Calvo et al., 2007, 2010). This aegyptin is also identical in
sequence to that of A. aegypti salivary allergen “Aed a 3” (gi|
205525920), a protein shown to induce allergic responses in both
mice and humans (Chen et al., 1998). Additionally, other research-
ers have found an association between serum reactivity to Aed a
3 and the dengue fever (mild) disease state in clinical patients in
Thailand (Machain-Williams et al., 2012). While the two aegyptin
groups represent distinct subclades, the acidic (glycine-, aspartic
acid-, and glutamic acid-rich) aminoterminal domain and the
more complex carboxyterminal domain characteristic of this
protein family remain conserved (Ribeiro et al., 2010).
The goal of this study was to determine the impact of the
A. aegypti salivary protein aegyptin on DENV infection kinetics and
the corresponding vertebrate immune response, in light of the
allergenic and anti-clotting effects already ascribed to this protein.
We designed two in vivo murine experiments examining the two
vertebrate facets critical to mosquito-borne viral transmission: estab-
lishment of DENV infectionwithin the bite site of the vertebrate host,
and systemic infection (circulation) that enables transmission from
the vertebrate to naïve mosquitoes. The time point of the ﬁrst
experiment, 48 h post-inoculation, is the day most often observed
for the onset of DENV viremia in these mice (Christofferson et al.,
2013), and as such potential differences seen in the bite site and
draining lymph nodes were assumed to be near their peaks. Mice for
the second experiment were examined daily through the end of
viremia for differences that have the potential to lead to differential
acquisition by the vector, such as differences in the magnitude of
viremia titers or day of viremia onset (Nguyet et al., 2013).
The addition of aegyptin to the DENV inoculum resulted in
signiﬁcantly decreased viral titers in the inoculated ears 48 h post-
inoculation, which could provide a rationale for the DENV2-
induced reduction of aegyptin in the saliva of infected mosquitoes.
It may be that this reduction in expectorated aegyptin decreases
the likelihood of an allergen-related or otherwise inﬂammatory
immune response at the bite site. As an extreme example, humans
bitten by mosquitoes lacking the ability to expectorate saliva failed
to manifest wheals (Rossignol and Spielman, 1982). Mosquito
saliva also has been shown previously to induce numerous
immunological reactions at the site of inoculation including
T-cell-mediated hypersensitivities, IgE-independent mast cell
degranulation, and immune cell recruitment (Peng and Simons,
2007). Lymph node GM-CSF, IFN-γ, IL-5, and IL-6, as well as the
percentage of eosinophils in circulation, were observed to be
greater in the DENVþaegyptin mice than in mice inoculated with
DENV alone at this time point. GM-CSF was demonstrated pre-
viously to promote growth, maturation, and survival of eosino-
phils, a pro-inﬂammatory granulocyte typically associated with
immune responses to allergens (Metcalf et al., 1986; Vliagoftis
et al., 2001). IL-6 is known to be an important mediator of the
acute phase response to infection and other antigenic stimuli, and
its inﬂuences have been reviewed previously (Heinrich et al.,
1990). IFN-y and IL-5 promote the activation and survival of
phagocytes and eosinophils, respectively, inﬂuence B cell isotype
switching events, and are involved in allergic immune responses
(Cho et al., 2005; Deenick et al., 2005; Horikawa and Takatsu,
2006; Schulten et al., 2013). A reduction or alteration in these
immune responses via a reduction in expectorated aegyptin could
beneﬁt the establishment of DENV within the vertebrate host. As a
consequence of lessened aegyptin in the site of viral establish-
ment, there may be less non-speciﬁc destruction of virions or
Fig. 3. Comparison of circulating leukocyte percents (counts) at 48 h post-inocula-
tion for the DENVþaegyptin inoculated cohort (AV) compared to the virus only
cohort (V). Comparisons of each leukocyte were performed using odds ratios and
signiﬁcance is indicated by an asterisk (pr0.05). Ninety-ﬁve percent conﬁdence
intervals are displayed.
Fig. 4. DENV viremia titers in serum samples on the ﬁrst six days post-inoculation.
DENV titers, expressed as PFU-equivalents/mL (PFU*/mL) were signiﬁcantly lower
in mice inoculated with DENVþaegyptin as compared to those inoculated with
virus alone on day 2 post-inoculation. DENV titers were signiﬁcantly higher in mice
inoculated with DENVþaegyptin as compared to those inoculated with virus alone
on day 5 post-inoculation. Signiﬁcance is indicated by an asterisk (pr0.05).
Associated bars represent standard error of the means.
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infected cells by local inﬂammation, cytokine-mediated cellular
activation, and eosinophil-derived degranulation.
Importantly, the addition of aegyptin to the DENV inoculum of
the serially bled cohort of mice resulted in an approximately
three-fold reduction in viremia titer on day two post-inoculation,
which corresponds to the decrease seen in the inoculation site at
48 h post-inoculation. Analogously, a reduction in expectorated
aegyptin, as was observed in DENV infected A. aegypti mosquitoes,
may result in greater viremia titers at this time point, which has
been shown to lead to increased acquisition rates by mosquitoes
from human clinical patients (Chisenhall et al., 2014b; Nguyet et
al., 2013). The increase in DENVþaegyptin viremia titer seen on
day 5 post-inoculation (mean¼4.36 PFU*/mL) may not result in
meaningful differences in transmission when compared to the
DENV alone cohort (mean¼1.39 PFU*/mL) given the relatively
minimal magnitude of these titers. Alternatively, the signiﬁcance
of changes at these two time points may have a more epidemio-
logical importance. Mosquitoes have been shown to successfully
acquire DENV up to two days prior to the onset of illness in human
cases, at which time these individuals may seek medical attention
or otherwise sequester themselves from access by mosquitoes
(Nishiura and Halstead, 2007). As such, the minimization of
contact between clinically ill individuals and mosquitoes might
select for a viral phenotype that induces decreased expression of
aegyptin, thereby resulting in greater early (potentially prodromal)
viremia rather than late viremia enhancement.
Conclusion
The inﬂuence of aegyptin on DENV infections of mice was
exempliﬁed by decreased viral titers early in the infection in
inoculation sites and in circulation, and by a day with increased
viremia titer late in infection. These modulations of DENV infec-
tion corresponded to increases in cytokines with known functions
in pro-inﬂammatory and allergen-mediated immune responses, as
well as an increased likelihood of eosinophil production. Together,
these data support a role for aegyptin in the modiﬁcation of the
host immune response during DENV infection. The role of aegyptin
in a naturally introduced DENV infection of humans may be
additionally inﬂuenced by other, co-expectorated saliva proteins,
as well as prior immunity to aegyptin or the same. Future studies
should seek to further characterize pro- and anti-viral aspects of
mosquito saliva-DENV interactions in the context of human infec-
tion and immunity.
Materials and methods
All experiments met the approval and conditions of the LSU
Institutional Animal Care and Use Committee (protocol #12-079).
LSU IACUC procedures and policies adhere to and comply with the
guidelines stated in the NIH Guide for the Care and Use of
Laboratory Animals.
Mice
Mice were the generous gift of Dr. M. Diamond (Washington
University, St. Louis, MO) with permission from Dr. T. Taniguchi
(University of Tokyo, Tokyo, Japan). These IRF-3/7/ / mice are
on a C57Bl/6 background and lack functional IRF 3 and 7, and as
such have a deﬁcient, but not abrogated, type I IFN response
(Dafﬁs et al., 2009).
Virus
Dengue serotype 2 (DENV2), strain 1232 was propagated
as described previously, with modiﬁcation (Christofferson and
Mores, 2011). Brieﬂy, we inoculated a T-75 ﬂask of conﬂuent Vero
cells with 100 ml of viral stock and incubated for 30 min. Eight mL
of Medium 199 with Earle's salts (M199E) with 10% fetal bovine
serum and 2% penicillin/streptomycin/amphotericin B was added.
The ﬂask was incubated at 37 1C with 5% CO2 for 5 days and
subsequently the supernatant was collected for virus at peak titer.
The viral titer of the supernatant was determined using a plaque
assay as described previously in Supplemental material, with
modiﬁcation (Alto et al., 2008). The complete medium stated
above was used and incubations occurred at 37 1C. This strain
was originally isolated from a patient in Indonesia in 1978
(personal communication, R. Tesh). As of this study, it has been
passaged four times in Vero cells, and then alternatingly passaged
between C6/36 (Aedes albopictus cell line) and Vero twice.
Mouse exposure and sample collection
Recombinant aegyptin was generated at a concentration of
9 mM in 25 mM Tris 150 mM NaCl, pH 7.4. It was expressed as
described previously in HEK293 cells and has a 6x-His tag (Calvo
et al., 2007). Aegyptin was diluted 1/10 in 0.2 μm-ﬁltered 1
phosphate-buffered saline (PBS) for experimentation.
Inoculation site mice
A total of 17 male and female mice, age 15 weeks, were divided
into four treatment groups and inoculated in the pinnae of both
ears via 25 μL intradermal injection. These groups were DENV
(n¼5), DENVþaegyptin (n¼5), aegyptin (n¼3), and a mock
inoculation (n¼4). The compositions of the inocula were as
follows: DENV  10 μL DENV (1105 PFU total in cell culture
supernatant)þ15 μL 1 PBS; DENVþaegyptin  10 μL DENVþ
2 μL aegyptin 1/10þ13 μL 1 PBS; aegyptin only  10 μL age-
matched cell culture supernatantþ2 μL aegyptin 1/10þ13 μL 1
PBS; mock  10 μL age-matched cell culture supernatantþ15 μL
1 PBS. Forty-eight hours later, mice were euthanatized accord-
ing to our IACUC protocol, and blood was collected via cardiac
puncture using ethylenediaminetetraacetic acid (EDTA)-coated
syringes and then placed into EDTA-coated BD Microtainers™
tubes (Becton, Dickinson, and Company, Franklin Lakes, NJ). This
blood was used for the creation of blood ﬁlms for quantiﬁcation of
circulating leukocytes and then centrifuged at 1000 relative
centrifugal force (rcf) for 10 min for plasma separation for use in
cytokine protein and viral RNA analysis. Inoculated ears and
draining submandibular lymph nodes were also collected and
processed for cytokine protein and viral RNA analysis. Individual
mouse ears and lymph nodes were disrupted and homogenized in
100 μL and 20 μL, respectively, of 1 PBS using the TissueLyser
(QIAGEN, Valencia, CA) for two cycles of 2 min at 25 Hz. For
cytokine analysis, 60 μL and 10 μL of the homogenized ear and
lymph node solutions were placed in 440 μL and 40 μL, respec-
tively, of radioimmunoprecipitation assay (RIPA) lysis buffer
(25 mM Tris–HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS) diluted 1/5 in 1 PBS containing protease
inhibitor (cOmplete, Mini, EDTA-free protease inhibitor cocktail
tablets, Roche, Indianapolis, IN). For viral RNA detection, 20 μL and
5 μL of the homogenized ear and lymph node solutions were
placed into 600 μL and 350 μL, respectively, of QIAGEN’s RLT buffer
with β-mercaptoethanol and vortexed. RNA was extracted using
the RNeasy Tissue Mini Kit (QIAGEN, Valencia, CA).
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Serially bled mice
A total of 19 female mice, age 1072 weeks, were divided into
two treatment groups and inoculated in the pinnae of one ear or
rear footpad via 25 μL intradermal injection. These groups were
DENV (n¼9) and DENVþaegyptin (n¼10). The compositions of
the inocula were as above, with a DENV titer determined to be
6.7104 PFU total. Mice were bled via submandibular vein punc-
ture immediately prior to inoculation and then daily for the next
6 days (Golde et al., 2005). This blood was collected in microcen-
trifuge tubes, allowed to clot for thirty minutes at room tempera-
ture, and then centrifuged at 3300 rcf for four minutes. Clariﬁed
serum was collected and placed into clean microcentrifuge tubes
for nucleic acid extraction using the MagMax-96 Total Nucleic Acid
isolation kit (Ambion/Life Technologies, Carlsbad, CA) and subse-
quent quantitative reverse-transcriptase polymerase chain reac-
tion (qRT-PCR) measurement of viremia.
Hematology
Differential leukocyte counts were performed in a blinded
manner by a board-certiﬁed veterinary clinical pathologist, as
previously described, in order to examine circulating leukocyte
populations during the inoculation site and serially bled mouse
studies (Grasperge et al., 2012). Brieﬂy, blood ﬁlms were made
within one hour of collection. Blood ﬁlms were Wright Giemsa
stained and counted in duplicate for differentiation of lympho-
cytes, monocytes, eosinophils, and basophils. Blood in EDTA was
diluted 1:100 in 2% acetic acid and incubated for 10 min at room
temperature. Total nuclei were counted in duplicate for each
mouse using this blood-acetic acid solution on a hemocytometer
in order to derive absolute leukocyte concentrations. Absolute
leukocyte concentrations and differential counts were then used
to calculate the absolute differential leukocyte concentrations.
Viral detection
Before inoculation, DENV was titered via plaque assay and
experimental titers from cell culture supernatant were conﬁrmed
by qRT-PCR as previously described (Christofferson and Mores,
2011). DENV RNA was extracted using the MagMax-96 Total
Nucleic Acid isolation kit (Ambion/Life Technologies, Carlsbad,
CA) or RNeasy Tissue Mini Kit (QIAGEN, Valencia, CA). Serum
samples were brought to volume where necessary with BA-1
diluent (M199E, 10% bovine serum albumin, 0.1 g/L L-glutamine,
2.2 g/L sodium bicarbonate, 25 mM HEPES, 2% penicillin/strepto-
mycin/amphotericin B, titrated to 7.4 pH with Tris and HCl) and
kits were run per manufacturers’ instructions (Chisenhall et al.,
2008). Detection of DENV RNA in mice was performed using the
Superscripts III Platinums One-Step qRT-PCR system (Life Tech-
nologies, Carlsbad, CA). Serial dilutions of DENV culture super-
natant (from above) were quantiﬁed via plaque assay, extracted
alongside samples, and used to generate the qRT-PCR standard
curve for estimation of DENV titer. Thus, viral concentrations are
expressed as PFU-equivalents/mL where appropriate, symbolized
as PFU*/mL.
Cytokine measurement
Granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon (IFN)-γ, IFN-γ-inducible protein-10 (IP-10), tumor
necrosis factor (TNF)-α, interleukin (IL)-1a, IL-2, IL-4, IL-5, IL-6,
IL-10, and IL-12p70 were measured in the inoculation sites,
draining lymph nodes, and serum at 48 h post-inoculation in the
inoculation site cohort of mice using the Milliplexs MAP Mouse
Cytokine/Chemokine kit (EMD Millipore, Billerica, MA) as per
manufacturer's instructions.
Statistical analysis
Tissue viral titers and cytokine levels were statistically analyzed
using analysis of variance (ANOVA). Leukocyte values were ana-
lyzed using odds ratios. These analyses were performed in SAS 9.13
(Carey, NC). Viremia titers were statistically analyzed using
grouped t-test by day in GraphPad Prism version 6.0b for Mac
OS X (San Diego, CA). Signiﬁcance is reported at the α¼0.05 level.
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